The Most Important Label Change in Women’s Health Since 2002 and the 5 Questions It Means You Should Ask

For more than twenty years, a black box warning kept women away from menopause hormone therapy. In February 2026, the FDA removed it. In this episode, I break down what changed, what the science actually says about hormone replacement therapy (HRT), and how to have a smarter conversation with your doctor about estrogen, progesterone, and your menopause symptoms.My own perimenopause story started two weeks after a half marathon personal record: joint pain, brain fog, insomnia, and cholesterol changes that sent me digging into the research. What I found is that the study behind the warning, the Women’s Health Initiative, enrolled women with an average age of 63 on a formulation rarely prescribed today. When researchers reanalyzed the data by age, women in their 50s with moderate to severe hot flashes showed neutral cardiovascular risk. I walk you through the breast cancer numbers, why the type of progestogen matters, the difference between oral and transdermal estrogen, the truth about bioidentical and compounded hormones, and the one warning that stayed.What you’ll learn:* Why the FDA removed the black box warning from hormone therapy and what the new labels say* What the Women’s Health Initiative study actually tested and who it was misapplied to* How breast cancer risk differs with micronized progesterone versus synthetic progestins* Why transdermal estrogen carried no increased blood clot risk while oral estrogen did* The five questions to bring to your hormone therapy conversation with your clinician* Green flags and red flags for telehealth menopause prescribersDr. Marbas Substack Article: https://drlauriemarbas.substack.com/p/the-most-important-label-change-inCheck out the Habit Healers Community: https://www.skool.com/habithealers/about Get full access to The Habit Healers at drlauriemarbas.substack.com/subscribe